Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization for international execution of Study SP-03-B101. This move follows recent regulatory approvals supporting study expansion and marks the transition of the Sapu003 program from an Australia-based clinical effort toward a broader multinational development strategy, including planned expansion into Europe.
SP-03-B101 is an open-label Phase 1b dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors. The company said GCT has already completed key regulatory submissions ahead of schedule and initiated clinical operations, site activation and study management activities. Sapu003 is an intravenous formulation of everolimus developed using Sapu Nano’s Deciparticle platform, which is designed to improve drug delivery and provide more predictable systemic exposure than oral administration while supporting future global registrational studies. The full press release is available at https://nnw.fm/olX92.
The expansion of the Sapu003 program is significant because it addresses the need for improved drug delivery in cancer treatment. Everolimus, an mTOR inhibitor, is currently available orally, but intravenous administration may offer benefits such as more predictable drug levels in the bloodstream and potentially better tumor targeting. This could lead to improved efficacy and reduced side effects for patients with advanced solid tumors that are sensitive to mTOR inhibition. The shift to a multinational study also accelerates the development timeline and brings the therapy closer to potential global approval.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes. Additionally, Oncotelic owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates. More information is available in the company's newsroom at https://nnw.fm/OTLC.
The appointment of Global Clinical Trials as lead CRO is a strategic move to ensure efficient international study execution. GCT’s early completion of regulatory submissions and initiation of clinical operations indicate a streamlined path forward. For patients with advanced mTOR-sensitive solid tumors, this development represents potential access to a new treatment option that could offer better tolerability and efficacy. For the industry, the Sapu003 program exemplifies the trend toward reformulating existing drugs to improve their therapeutic profiles, which could lead to more effective cancer therapies.
